Sanofi Continues Consumer Health Trim, Sells Kaopectate US Rights To Arcadia
Sanofi sells US rights to anti-diarrhea Kaopectate brand to Arcadia Consumer Healthcare, which plans to invest in marketing and innovation behind the brand. Arcadia also markets the Nizoral dandruff shampoo and Fungi-Nail consumer health brands.
You may also be interested in...
With Consumer Healthcare sales down for Sanofi in 2019, CEO Hudson says the firm must do more to turn performance around. Key to achieving this will be the creation of a more agile standalone OTC business.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Sanofi's push to concentrate its Consumer Healthcare portfolio on priority categories sees it offload two OTC brands in Germany and Austria. Meanwhile, new Sanofi CEO Paul Hudson has spoken about his intention to review the firm's plans in the OTC market.